FDA.reportPublic FDA data

Apriso 375 MG 24 HR Extended Release Oral Capsule

RxCUI
825134
RxNorm name
Apriso 375 MG 24 HR Extended Release Oral Capsule
Display name
Apriso 375 MG 24 HR Extended Release Oral Capsule
Full name
Apriso 375 MG 24 HR Extended Release Oral Capsule
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
7951139c-b271-45a4-b523-34b23800917bApriso 0.375 GM 24HR Extended Release Oral Capsule [PSN] · 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] [SBD] · Apriso 375 MG 24 HR Extended Release Oral Capsule [SY]334These highlights do not include all the information needed to use APRISO safely and effectively. See full prescribing information for APRISO. APRISO ® (mesalamine) extended-release capsules Initial U.S. Approval: 198720240109
d5d05b1f-9f45-4f66-9f75-3c67934105deApriso 0.375 GM 24HR Extended Release Oral Capsule [PSN] · 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] [SBD] · Apriso 375 MG 24 HR Extended Release Oral Capsule [SY]32These highlights do not include all the information needed to use APRISO safely and effectively. See full prescribing information for APRISO. APRISO™ (mesalamine) extended-release capsules Initial U.S. Approval: 198720120215